Draft monograph: retatrutide — disposition

§3Disposition and amendments

§3.1Disposition table

Table 1. Every submission with its disposition. Each row links to the submission in full.

§3.2Summary by disposition

Table 2. Counts by disposition, with the meaning of each.

§3.3Resulting amendments

1. The document is unreadable without specialist training — arising from DRAFT-RETATRUTIDE-/003. Every document now opens with a plain-language summary of not more than 150 words, placed above the technical abstract and carrying the same certainty language, so that the two cannot diverge.
2. The analytical section assumes a reference standard that is not generally available — arising from DRAFT-RETATRUTIDE-/002. The analytical section now states whether a reference standard is in general circulation for this compound and, where it is not, states which determinations remain possible and which become qualitative. A content figure obtained without a reference standard…
3. The monograph should reproduce the approved labelling rather than paraphrase it — arising from DRAFT-RETATRUTIDE-/013. The approved indication and contraindications are now reproduced verbatim from the named authorisation with its version and date, and the posology section reports the labelled schedule and the schedules studied side by side, with the source of each stated.
4. The monograph does not tell a reader that a stated mass may be substantially counter-ion and water — arising from DRAFT-RETATRUTIDE-/011. The monograph now states, at the point where vial contents are first mentioned, that a mass figure is uninterpretable unless it states whether it is peptide content or total solids, and cross-references the content standard in the analytical series.
5. Storage and reconstitution guidance is given without stating what it rests on — arising from DRAFT-RETATRUTIDE-/014. In-use periods now appear only where supported by a cited stability determination on a stated presentation, and elsewhere the monograph records that no in-use stability evidence was identified for this presentation.
6. The same concept is given three different names in one document — arising from DRAFT-RETATRUTIDE-/001. A single term is now used throughout for each defined concept, and the glossary entry is linked at first use within each section rather than once per document.
7. Evidence for one member of the class is presented as evidence for this compound — arising from DRAFT-RETATRUTIDE-/008. Class-level inferences are now labelled at the point of use, are excluded from the certainty rating for the compound, and are reported in a separate subsection stating which compound the underlying evidence concerns.
8. Trials are described as terminated where they completed as planned — arising from DRAFT-RETATRUTIDE-/007. Trial status now uses a fixed vocabulary defined in the glossary, and where the reason for stopping is not evidenced by a document the Institute holds, the status is recorded as stopped with the reason not established rather than assigned.
9. Mechanistic claims for a peptide fragment are carried without evidence that the fragment acts as… — arising from DRAFT-RETATRUTIDE-/009. Mechanistic claims not traceable to a primary source are removed, and those retained carry their source and a statement of whether the underlying work was conducted in vitro, in animals or in humans.

References cited on this page

References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.

1. International Organization for Standardization. ISO/IEC 17025:2017 General Requirements for the Competence of Testing and Calibration Laboratories. ISO/IEC Standard 2017;3rd edition. identifier not held by the Institute

Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.